AbCellera Biologics Inc. (ABCL)

NMS – Real vaqt narxi. Valyuta: USD

10.35

+0.58 (5.99%)

Yopilishda: Aug 12, 2026, 3:59 PM EDT

10.33

-0.02 (-0.24%)

Bozordan keyin: Aug 12, 2026, 6:51 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

AbCellera Biologics Inc. (ABCL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AbCellera Biologics Inc. (ABCL)

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

Videolar

No Data

Press-relizlar

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera Reports Q2 2026 Business Results

Search stocks

AbCellera Biologics Inc. (ABCL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AbCellera Biologics Inc. (ABCL)

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

Videolar

No Data

Press-relizlar

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera Reports Q2 2026 Business Results